$7.31
-0.05 (-0.68%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TIL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 3 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC) · FINRA short interest 17.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| ITIL-306 in Advanced Solid TumorsNCT05397093Frequency and severity of ITIL-306 treatment-emergent adverse events (AEs), serious AEs, and AEs of special interest (AESI)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was terminated early due to discontinuation of development of the investigational program | Biological: ITIL-306 | Epithelial Ovarian Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma | 1 | 2023-10-10actual | 2026-04-15 |
| ITIL-168 in Advanced MelanomaNCT05050006Objective response rateNon-randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Business Decision | Biological: ITIL-168 | Advanced Cutaneous Melanoma | 29 | 2023-02-27actual | 2024-04-16 |
| ITIL-168 in Advanced Solid TumorsNCT05393635Frequency and severity of ITIL-168 treatment-emergent adverse events (AEs), serious AEs, and AEs of special interestNon-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: business decision | Biological: ITIL-168 | Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer | 0 | 2022-12-08actual | 2022-12-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19